JP7749020B2 - 局所眼科用組成物 - Google Patents

局所眼科用組成物

Info

Publication number
JP7749020B2
JP7749020B2 JP2023547047A JP2023547047A JP7749020B2 JP 7749020 B2 JP7749020 B2 JP 7749020B2 JP 2023547047 A JP2023547047 A JP 2023547047A JP 2023547047 A JP2023547047 A JP 2023547047A JP 7749020 B2 JP7749020 B2 JP 7749020B2
Authority
JP
Japan
Prior art keywords
ophthalmic composition
topical ophthalmic
atropine
concentration
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023547047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511695A (ja
JP2024511695A5 (https=
Inventor
ニ，ジンソン
ディン，ヴァン
ヤン，ロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADS Therapeutics LLC
Original Assignee
ADS Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADS Therapeutics LLC filed Critical ADS Therapeutics LLC
Publication of JP2024511695A publication Critical patent/JP2024511695A/ja
Publication of JP2024511695A5 publication Critical patent/JP2024511695A5/ja
Priority to JP2025157079A priority Critical patent/JP2025176201A/ja
Application granted granted Critical
Publication of JP7749020B2 publication Critical patent/JP7749020B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023547047A 2021-02-03 2022-02-02 局所眼科用組成物 Active JP7749020B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025157079A JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145091P 2021-02-03 2021-02-03
US63/145,091 2021-02-03
PCT/US2022/014811 WO2022169788A1 (en) 2021-02-03 2022-02-02 Topical ophthalmological compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025157079A Division JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Publications (3)

Publication Number Publication Date
JP2024511695A JP2024511695A (ja) 2024-03-15
JP2024511695A5 JP2024511695A5 (https=) 2025-04-21
JP7749020B2 true JP7749020B2 (ja) 2025-10-03

Family

ID=82741579

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023547047A Active JP7749020B2 (ja) 2021-02-03 2022-02-02 局所眼科用組成物
JP2025157079A Pending JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025157079A Pending JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Country Status (8)

Country Link
US (2) US12070501B1 (https=)
EP (1) EP4288151A4 (https=)
JP (2) JP7749020B2 (https=)
KR (1) KR20230142548A (https=)
AU (1) AU2022217160A1 (https=)
CA (1) CA3206612A1 (https=)
MX (1) MX2023009091A (https=)
WO (1) WO2022169788A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268457B (en) * 2019-08-04 2022-05-01 Omega 3 Galilee Ltd Oil- suspension of edible solids and methods of preparing the same
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN119789854A (zh) * 2023-08-04 2025-04-08 Ads医疗有限责任公司 用于递送眼科活性物的组合物和方法
WO2025131038A1 (en) * 2023-12-21 2025-06-26 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2026003129A1 (en) * 2024-06-26 2026-01-02 Novaliq Gmbh Stabilization of (r)-ruxolitinib

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526051A (zh) 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
JP2015531344A (ja) 2012-09-12 2015-11-02 ノバリック ゲーエムベーハー 半フッ化アルカンの混合物を含む組成物
JP2017522292A (ja) 2014-06-24 2017-08-10 シドネキシス，インク． 眼科用組成物
JP2018507239A (ja) 2015-03-05 2018-03-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼科用薬物送達のための自己乳化薬物送達システム（ｓｅｄｄｓ）
JP2023544853A (ja) 2020-10-08 2023-10-25 エーディーエス・セラピューティクス・エルエルシー 局所眼科用組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE10030378A1 (de) 2000-06-21 2002-03-14 Audit Inst For Medical Service Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
US20100323978A1 (en) * 2009-06-22 2010-12-23 Calvin Hanna Non-aqueous oil delivery system for ophthalmic drugs
PL2547323T3 (pl) 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
AU2017333420A1 (en) 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
BR112019012568A2 (pt) 2016-12-22 2019-11-26 Novaliq Gmbh composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias
PH12019501945B1 (en) 2017-02-21 2024-02-21 Singapore Health Serv Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
WO2018228975A1 (en) 2017-06-12 2018-12-20 Novaliq Gmbh Process for the preparation of semifluorinated alkanes using grignard reagents
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020152046A1 (en) 2019-01-21 2020-07-30 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
CA3128224A1 (en) * 2019-02-01 2020-08-06 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526051A (zh) 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
JP2015531344A (ja) 2012-09-12 2015-11-02 ノバリック ゲーエムベーハー 半フッ化アルカンの混合物を含む組成物
JP2017522292A (ja) 2014-06-24 2017-08-10 シドネキシス，インク． 眼科用組成物
JP2018507239A (ja) 2015-03-05 2018-03-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼科用薬物送達のための自己乳化薬物送達システム（ｓｅｄｄｓ）
JP2023544853A (ja) 2020-10-08 2023-10-25 エーディーエス・セラピューティクス・エルエルシー 局所眼科用組成物

Also Published As

Publication number Publication date
AU2022217160A9 (en) 2025-01-30
JP2024511695A (ja) 2024-03-15
WO2022169788A1 (en) 2022-08-11
KR20230142548A (ko) 2023-10-11
CA3206612A1 (en) 2022-08-11
MX2023009091A (es) 2023-08-09
JP2025176201A (ja) 2025-12-03
US20250000980A1 (en) 2025-01-02
US12070501B1 (en) 2024-08-27
EP4288151A1 (en) 2023-12-13
US12485177B2 (en) 2025-12-02
EP4288151A4 (en) 2025-01-01
AU2022217160A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
JP7749020B2 (ja) 局所眼科用組成物
JP2023544853A (ja) 局所眼科用組成物
JP6824270B2 (ja) 生物活性親油性化合物を有するｐｅｇ化脂質ナノ粒子
JP6348567B2 (ja) マイクロエマルジョン局所送達プラットフォーム
KR20200128407A (ko) 네비볼롤을 포함하는 약제학적 조성물
CA2780453A1 (en) Treating xerophthalmia with compounds increasing meibomian gland secretion
JP2016512562A5 (https=)
El-Haddad et al. Down regulation of inflammatory cytokines by the bioactive resveratrol-loaded chitoniosomes in induced ocular inflammation model
US20260124305A1 (en) Topical ophthalmological compositions
CN120093684A (zh) 局部眼科组合物
CN117883380A (zh) 一种用于治疗干眼症的经皮给药的乳剂
JPH08508975A (ja) 眼科薬送達ビヒクルとしてのサブミクロン乳剤
CN112294761A (zh) 一种难溶性药物的眼用胶束制剂
CN116322664A (zh) 神经保护的方法及其用途
HK40086649A (zh) 局部眼科组合物
RU2827551C2 (ru) Лечение заболеваний глаз
RU2816363C2 (ru) Лечение заболевания глаз
Singh et al. Adverse effects of antiglaucoma medications: pathophysiology and novel drug delivery strategies for mitigation
WO2026018131A1 (en) Ocular compositions
US20240009124A1 (en) Ophthalmic Suspension Base having a Micro-fluidized Positively Charged Nanoparticle
HK40044057A (en) Pharmaceutical compositions comprising nebivolol
Sahu et al. In-situ gel ocular drug delivery system for the management of ocular disorders: An overview
HK40044057B (zh) 包含奈必洛尔的药物组合物
JPH06511014A (ja) 眼への投与に用いる、緩衝剤系を含有するベラパミル塩酸製剤などの眼科用液剤
HK1166608B (en) Anionic oil-in-water emulsions containing prostaglandins and uses thereof

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250922

R150 Certificate of patent or registration of utility model

Ref document number: 7749020

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150